Clinical Trials on Hepatocellular Injury

Total 12422 results

Henan Cancer Hospital

Not yet recruiting

Radiofrequency Ablation Combined With Toripalimab and Lenvatinib in the Treatment of Short-term Recurrent Hepatocellular Carcinoma.

Recurrent Hepatocellular Cancer
Tianjin Medical University Cancer Institute and...

Recruiting

Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Novartis Pharmaceuticals

Terminated

Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma With c-MET Dysregulation

China, Hong Kong, Thailand, Singapore
Chang Gung Memorial Hospital
Ministry of Science and Technology, Taiwan

Completed

The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma (SOX4 in HCC)

Translational Research of SOX4 in Hepatocellular Carcinoma
Chang Gung Memorial Hospital

Completed

Hypermethylation of VTRNA2-1 Promoter in HCC Outcome

Hepatocellular Carcinoma Resectable

Taiwan
University of British Columbia

Completed

TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) (TACE)

Unresectable Hepatocellular Carcinoma | Undergoing Chemoembolization and Radioembolization

Canada
Ain Shams University

Completed

Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt

Hepatocellular Carcinoma (HCC) | Living Donor Liver Transplantation
Second Military Medical University

Unknown

Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC

Chemotherapy Effect | BCLC Stage C Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Resectable Hepatocellular Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
First Affiliated Hospital of Wenzhou Medical University
Qilu Hospital of Shandong University; Eastern Hepatobiliary Surgery Hospital; The First Affiliated Hospital of Zhejiang Chinese Medical University

Enrolling by invitation

Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)

Hepatocellular Carcinoma Non-resectable | Effect of Drug

China
Cancer Hospital of Guangxi Medical University

Active, not recruiting

Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma

TACE | Lenvatinib | Tislelizumab | Advanced Unresectable Hepatocellular Carcinoma

China
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

Advanced Hepatocellular Carcinoma

United States, China, Italy, Japan, Korea, Republic of, Poland, Spain, Switzerland, Taiwan
Novartis Pharmaceuticals

Withdrawn

Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Germany, Australia, Hong Kong, Switzerland, Spain, France, United States
Eastern Hepatobiliary Surgery Hospital

Completed

The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene

Hepatocellular Carcinoma; | Radical Hepatic Resection;

China
Sun Yat-sen University

Not yet recruiting

AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)

Resectable Hepatocellular Carcinoma
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET-III)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Sun Yat-sen University

Withdrawn

Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT

Advanced Hepatocellular Carcinoma

China
SignalRX Pharmaceuticals, Inc.
University of California, San Diego

Terminated

Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

United States
Daiichi Sankyo, Inc.

Completed

CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer

Liver Neoplasms | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer

Korea, Republic of, Taiwan, United States, Japan
Shanghai Zhongshan Hospital

Unknown

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Institut National de la Santé Et de la Recherche...

Completed

Mutational Landscape in Hepatocellular Carcinoma (MUTHEC)

Cirrhosis | HepatoCellular Carcinoma

France
Ain Shams University

Completed

Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis

Hepatocellular Carcinoma (HCC)
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT

Hepatocellular Carcinoma Non-resectable

China
Suzhou Kintor Pharmaceutical Inc,

Completed

Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)

HCC | Metastatic Hepatocellular Carcinoma | Combinations of Drugs; Dependence

Taiwan
Helio Genomics
Helio Health Inc., Irvine, CA; Laboratory for Advanced Medicine, Guangzhou

Completed

Performance Evaluation (Sensitivity/Specificity) of HelioLiver Test for Detection of HCC (ENCORE)

Hepatocellular Carcinoma by AJCC Stage

China
Eastern Hepatobiliary Surgery Hospital

Unknown

Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma With CSPH

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Preoperative Stereotactic Body Radiotherapy (SBRT) Followed by Hepatectomy for Centrally Located Hepatocellular Carcinoma: a Prospective, Single-center, Phase I Study

Hepatectomy | Stereotactic Body Radiotherapy | Centrally Located Hepatocellular Carcinoma

China
Yongchang Zhang

Recruiting

Radiotherapy + Sintilimab + Bevacizumab Biosimilar for uHCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
Ludwig-Maximilians - University of Munich

Recruiting

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (DEMAND)

Hepatocellular Carcinoma Non-resectable

Germany
Second Affiliated Hospital of Guangzhou Medical...
First People's Hospital of Foshan; Huizhou Municipal Central Hospital; Zhongshan... and other collaborators

Completed

Lenvatinib Plus DEB-TACE With/Without FOLFOX-HAIC for Large HCC With PVTT

Hepatocellular Carcinoma Non-resectable

China
University of Michigan Rogel Cancer Center
Exelixis

Active, not recruiting

Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy

Advanced Adult Hepatocellular Carcinoma

United States
Fuda Cancer Hospital, Guangzhou

Withdrawn

CAR-T Cell Immunotherapy for HCC Targeting GPC3

CAR-T Cell Immunotherapy | GPC3 Positive Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC (PLTHCC)

Hepatocellular Carcinoma Non-resectable

China
Fan Weijun

Unknown

Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge

Hepatocellular Carcinoma Non-resectable | Microwave Ablation | Transarterial Chemoembolization

China
Albert Einstein College of Medicine
National Cancer Institute (NCI)

Completed

Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Terminated

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Advanced Adult Hepatocellular Carcinoma | Localized Non-Resectable Adult Liver Carcinoma | Recurrent Adult Liver Carcinoma | Adult Hepatocellular Carcinoma

United States
Sun Yat-sen University

Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma | Bevacizumab | Anti-PD1/PDL1 Antibody

China
Fujian Cancer Hospital

Recruiting

Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma

Stage IIIA Hepatocellular Carcinoma

China
Thomas Jefferson University

Completed

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective

Advanced Liver Cancer | Metastatic Hepatocellular Carcinoma

United States
Zhang Bi Xiang, MD

Recruiting

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma (CCGLC-003)

Hyperbaric Oxygen Therapy | Combinational Immunotherapy | Hepatocellular Carcinoma Non-Resectable

China
Kindai University

Unknown

Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS)

Carcinoma, Hepatocellular | Hepatocellular Carcinoma | Liver Neoplasm | Unresectable Hepatocellular Carcinoma

Japan
Tianjin Medical University Cancer Institute and...

Recruiting

Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy

China
Sohag University

Recruiting

Paraneoplastic Syndrome in Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma Patients

Egypt
University Hospital, Rouen

Recruiting

Cohort Study of Patients With Hepatocellular Carcinoma and Circulating Tumor DNA Monitoring of Chemoembolization (Mona-Lisa)

Hepatocellular Carcinoma Non-resectable | Circulating Tumor DNA | Transarterial Chemoembolization

France
Yonsei University
GE Healthcare

Completed

Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study

Hepatocellular Carcinoma (HCC)

Korea, Republic of
H3 Biomedicine Inc.
Eisai Inc.

Completed

Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Liver Neoplasms | Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Liver Cancer | Hepatic Cancer | Hepatic Carcinoma

France, United States, Belgium, Spain, Taiwan, Korea, Republic of, Russian Federation, Canada, Italy, Singapore, United Kingdom

Clinical Trials on Hepatocellular Injury

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations